The NDA submission follows the successful completion of a pivotal Phase III global clinical trial
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen is bioequivalent to Victoza Injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk
The acquisition positions ACL Digital as an end-to-end provider of global clinical research and data CRO solutions
The expansion will significantly enhance AbbVie’s ability to meet growing global demand for biologics, particularly in oncology and immunology
Subscribe To Our Newsletter & Stay Updated